

# Morgan Lewis



**BLOCKBUSTER BIOLOGICS REVIEW** ISSUE 11

## Legislative Updates

- > **President signed Consolidated Appropriations Act on December 27, 2020**
  - > Permits, but does not require, aBLAs to include information showing that the biosimilar's conditions of use are the same as conditions of use approved
  - > Requires FDA to create a searchable electronic list of licensed biologics, provide monthly updates to the list, and include in the list exclusivities and patent information included on (3)(A) lists
    - > A request for public comment will occur in 2023 regarding what should be added to or deleted from the list

# Contacts



**Christopher J. Betti, Ph.D.**  
Chicago  
T: +1.312.324.1449  
christopher.betti@morganlewis.com



**Robin M. Silva**  
San Francisco  
T: +1.415.442.1379  
robin.silva@morganlewis.com



**Maria E. Doukas**  
Chicago  
T: +1.312.324.1454  
maria.doukas@morganlewis.com



**Kelly A. Plummer, Ph.D**  
Chicago  
T: +1.312.324.1490  
kelly.plummer@morganlewis.com